Pascal Potier
Overview
Explore the profile of Pascal Potier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Causse X, Potier P, Valery A, Labadie H, Macaigne G, Cadranel J, et al.
J Viral Hepat
. 2024 Dec;
32(1):e14041.
PMID: 39673688
Prognostic factors for the long-term evolution of chronic hepatitis B e antigen (HBeAg)-negative hepatitis B virus (HBV) infection may vary depending on local epidemiology. We aimed to identify these factors...
2.
Raqi I, Potier P, Lagasse J
Cureus
. 2024 Apr;
16(3):e57264.
PMID: 38686245
Introduction Acute lower gastrointestinal bleeding (LGIB) presents challenges in emergency settings, with incidence influenced by demographic shifts and anticoagulant usage. The Oakland score aids in risk stratification for safe discharge...
3.
Chazouilleres O, Potier P, Bouzbib C, Hanslik B, Heurgue A, Nguyen-Khac E, et al.
Clin Res Hepatol Gastroenterol
. 2021 Jul;
46(1):101775.
PMID: 34332142
Primary sclerosing cholangitis (PSC) is a rare and chronic cholestatic liver disease of unknown cause commonly associated with inflammatory bowel disease (IBD) and characterized by progressive obliterative fibro-inflammation of the...
4.
Corpechot C, Heurgue A, Tanne F, Potier P, Hanslik B, Decraecker M, et al.
Clin Res Hepatol Gastroenterol
. 2021 Jul;
46(1):101770.
PMID: 34332135
Primary biliary cholangitis (PBC) is a chronic inflammatory disease of the intra-hepatic bile ducts [1]. It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies, and...
5.
Marlet J, Lier C, Roch E, Moreau A, Combe B, Handala L, et al.
Antiviral Res
. 2021 Jul;
192:105106.
PMID: 34214504
Entecavir treatment failure can be observed in compliant patients despite an absence of detectable resistance mutations by Pol/RT Sanger sequencing. We hypothesized that these unexplained treatment failures could rely on...
6.
Soret P, Lam L, Carrat F, Smets L, Berg T, Carbone M, et al.
Aliment Pharmacol Ther
. 2021 Mar;
53(10):1138-1146.
PMID: 33764590
Background: Obeticholic acid (OCA) and fibrates are second-line therapies for patients with primary biliary cholangitis (PBC) with an inadequate response to ursodeoxycholic acid (UDCA). Aim: To know whether OCA and...
7.
Dong C, Condat B, Picon-Coste M, Chretien Y, Potier P, Noblinski B, et al.
JHEP Rep
. 2021 Feb;
3(2):100201.
PMID: 33554096
Background & Aims: Low-phospholipid-associated cholelithiasis (LPAC) syndrome, a rare genetic form of intrahepatic cholelithiasis in adults, is still poorly understood. We report the results of the largest-ever case-control study of...
8.
De Martin E, Coilly A, Chazouilleres O, Roux O, Peron J, Houssel-Debry P, et al.
J Hepatol
. 2021 Jan;
74(6):1325-1334.
PMID: 33503489
Background & Aims: In acute severe autoimmune hepatitis (AS-AIH), the optimal timing for liver transplantation (LT) remains controversial. The objectives of this study were to determine early predictive factors for...
9.
Ackerman M, Esteve E, Potier P, Finon A
Australas J Dermatol
. 2020 Nov;
62(2):e326-e327.
PMID: 33216960
No abstract available.
10.
Trosseille X, Petit P, Uriot J, Potier P, Baudrit P
Stapp Car Crash J
. 2020 Apr;
63:219-305.
PMID: 32311061
Several studies, available in the literature, were conducted to establish the most relevant criterion for predicting the thoracic injury risk on the THOR dummy. The criteria, such as the maximum...